JonesTrading analyst Soumit Roy has maintained their neutral stance on EDIT stock, giving a Hold rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Soumit Roy has given his Hold rating due to a combination of factors surrounding Editas Medicine’s recent developments. The company has shown promising preclinical results with their EDIT-401 program, which targets LDL-C reduction in cardiovascular disease. However, the data is still in early stages, and the company is not expected to submit an IND/CTA until mid-2026, with initial clinical data anticipated by the end of 2026.
While the preclinical results are encouraging, with significant LDL-C reduction and no concerning adverse events, the absence of human data and the timeline for further development contribute to the cautious Hold rating. Additionally, the financial aspects, such as the estimated cash burn and current cash reserves, suggest that while the company is progressing, there are still uncertainties that warrant a wait-and-see approach.
In another report released today, Barclays also maintained a Hold rating on the stock with a $3.00 price target.